Discovery of antigen and antibody profiles in response to yellow fever vaccination as a model for an infectio

Recruiting

• Conditions: Yellow Fever; A95; Yellow fever

• Registration Number: DRKS00032601
• Lead Sponsor: Abteilung für Infektions- und Tropenmedizin, LMU Klinikum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Eligible for Yellow fever vaccine due to travel or other reasons
- Available for majority of time points

Exclusion Criteria

- Allergies or known sensitivity to yellow fever vaccine or components of the vaccine
- Vaccination against Japanese encephalitis, FSME or Dengue 4 weeks prior or after the yellow fever vaccination
- known positivity for acute/active blood borne diseases such as HIV, HepC or HepB
-known condition leading to immuno-suppression e.g. solid cancer, known haematological abnormities
- immuno-suppressive drugs such as systemic steroids, chemotherapy, immunosuppressive treatment of
rheumatoid arthritis
- other known exclusion criteria for yellow fever vaccine

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main feature is the reactivity against yellow fever antigens over time in different formats such as lateral flow, cell neutralization, ELISA, or ELECSYS asays.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes, related to the main outcomes, are reactivity against other infectious diseases with particular emphasis on other flaviviral diseases such as TBE, dengue, etc., as severe cross reactivities are described in the literature that are relevant to the specificity of the test.